WW
Therapeutic Areas
Jasper Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Briquilimab (JSP191) | Conditioning for HSCT in Severe Combined Immunodeficiency (SCID) | Phase 1/2 / Pivotal Path |
Leadership Team at Jasper Therapeutics
RM
Ronald Martell
President and Chief Executive Officer
AF
Anna French, Ph.D.
Chief Operating Officer
SH
Scott Harris
General Counsel
ET
Edwin Tucker, M.D.
Chief Financial Officer
HB
Heather Behanna, Ph.D.
SVP, Investor Relations & Corporate Communications